Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow COR
Cencora, Inc. (COR) Return on equity
Cencora, Inc.'s return on equity over the twelve months to 30 June 2026 was 96.3%, down 26.3 percentage points from fiscal 2025 (122.7%). Over the past ten years it has ranged from −1,206.7% (fiscal 2021) to 518.2% (fiscal 2022); the current reading is higher than 73% of that period. That is above the Medical Distribution industry median of 0.00% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 122.7% | (85.05) |
| FY2024 | 207.7% | (265.54) |
| FY2023 | 473.3% | (44.92) |
| FY2022 | 518.2% | 1,724.91 |
| FY2021 | −1,206.7% | (890.17) |
| FY2020 | −316.6% | (344.87) |
| FY2019 | 28.3% | (36.54) |
| FY2018 | 64.9% | 47.47 |
| FY2017 | 17.4% | (86.63) |
| FY2016 | 104.0% | 114.75 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| COR Cencora, Inc. | 96.3% |
| ACH Accendra Health, Inc. compare | 72.6% |
| HSIC Henry Schein, Inc. compare | 10.2% |
| AHG Akso Health Group Sponsored ADR compare | 0.00% |
| HKPD Cellyan Biotechnology Co., Ltd compare | 0.00% |
| CAH Cardinal Health, Inc. compare | −64.0% |
| COSM Cosmos Health Inc. compare | −104.0% |
| FOCL FocalTherics compare | −133.5% |
| MCK McKesson Corporation compare | −168.5% |
| Medical Distribution industry median | 0.00% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on COR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement